政策密集出台！创新药商业模式有望整体改善

Core Viewpoint - The Xi'an Municipal Government has released an implementation plan to enhance the biopharmaceutical industry from 2025 to 2027, focusing on breakthroughs in key drug development technologies and supporting the research and commercialization of innovative drugs [1][2]. Group 1: Industry Goals - The plan sets three main objectives: achieving a biopharmaceutical industry scale of 40 billion yuan by 2027, with specific targets for traditional Chinese medicine (9 billion yuan), chemical drugs (12 billion yuan), biological drugs (6 billion yuan), and medical devices (13 billion yuan) [2]. - It aims to achieve clinical approval for one innovative drug and production approval for another by 2027, along with 40 Class III medical devices and 400 Class II medical devices [2]. Group 2: Innovation and Collaboration - The plan emphasizes the development of innovative drugs, particularly in areas such as targeted liver delivery drugs, peptide products, and addiction treatment drugs, while encouraging collaboration between pharmaceutical companies and academic institutions [3][4]. - It outlines a comprehensive innovation ecosystem for cell therapy, focusing on stem cell therapy, immune cell therapy, and cell-derived therapies, with a full chain from basic research to clinical application [4][5]. Group 3: Policy Support and Trends - Multiple cities, including Beijing, Shanghai, Chongqing, and Sichuan, have introduced policies to support the innovative drug industry, indicating a new cycle of policy support for the biopharmaceutical sector [7][8]. - The policies include expedited clinical trial approvals and financial support for innovative drug development, reflecting a trend towards enhancing the overall innovation ecosystem in the pharmaceutical industry [7][8].